Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo

The majority of human melanomas bears BRAF mutations and thus is treated with inhibitors of BRAF, such as vemurafenib. While patients with BRAF mutations often demonstrate an initial dramatic response to vemurafenib, relapse is extremely common. Thus, novel agents are needed for the treatment of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonner, Michael Y., Karlsson, Isabella, Rodolfo, Monica, Arnold, Rebecca S., Vergani, Elisabetta, Arbiser, Jack L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914326/
https://www.ncbi.nlm.nih.gov/pubmed/26871475
http://dx.doi.org/10.18632/oncotarget.7289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914326/
https://www.ncbi.nlm.nih.gov/pubmed/26871475
http://dx.doi.org/10.18632/oncotarget.7289

Ejemplares similares